Treatment of central serous chorioretinopathy with topical NSAIDs

Sepehr Bahadorani,1 Kyle Maclean,1 Kendall Wannamaker,1 Edward Rickie Chu,1 Nathan Gresores,2 Jeong-Hyeon Sohn,1 Roberto Diaz-Rohena,1 Michael A Singer21Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; 2Medical Center Ophthalmology Associat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bahadorani S, Maclean K, Wannamaker K, Chu ER, Gresores N, Sohn JH, Diaz-Rohena R, Singer MA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Central serous chorioretinopathy CSCR CSC CSR NSAIDs bromfenac nepafenac subretinal fluid SRF. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/3d09e27f5f2a41e68a9509b25d8f3f63
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3d09e27f5f2a41e68a9509b25d8f3f63
record_format	dspace
spelling	oai:doaj.org-article:3d09e27f5f2a41e68a9509b25d8f3f632021-12-02T04:29:28ZTreatment of central serous chorioretinopathy with topical NSAIDs1177-5483https://doaj.org/article/3d09e27f5f2a41e68a9509b25d8f3f632019-08-01T00:00:00Zhttps://www.dovepress.com/treatment-of-central-serous-chorioretinopathy-with-topical-nsaids-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Sepehr Bahadorani,1 Kyle Maclean,1 Kendall Wannamaker,1 Edward Rickie Chu,1 Nathan Gresores,2 Jeong-Hyeon Sohn,1 Roberto Diaz-Rohena,1 Michael A Singer21Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; 2Medical Center Ophthalmology Associates, San Antonio, TX, USAPurpose: Central serous chorioretinopathy (CSCR) is a common retinopathy that is often observed until resolution. The purpose of this study is to evaluate the effects of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on timing of CSCR recovery.Methods: An IRB-approved retrospective review was conducted on patients that had been diagnosed with a new-onset, symptomatic case of CSCR. Patients were either observed only (13 untreated eyes) or treated with topical bromfenac or nepafenac (14 eyes) over an average of about a 4–5 week follow-up period.Results: There was no statistical significance between central macular thickness (CMT) and visual acuity of treatment and control groups at the initial presentation. However, at the follow-up visit, CMT reductions in the treatment group were significantly higher than in the control group (p<0.006).Conclusion: Use of topical NSAIDs in the treatment of acute CSCR leads to a faster rate of reduction in the subretinal fluid volume over a follow-up period of a few weeks.Keywords: central serous chorioretinopathy, CSCR, CSC, NSAIDs, bromfenac, nepafenac, subretinal fluid, SRFBahadorani SMaclean KWannamaker KChu ERGresores NSohn JHDiaz-Rohena RSinger MADove Medical PressarticleCentral serous chorioretinopathyCSCRCSCCSRNSAIDsbromfenacnepafenacsubretinal fluidSRF.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 1543-1548 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Central serous chorioretinopathy CSCR CSC CSR NSAIDs bromfenac nepafenac subretinal fluid SRF. Ophthalmology RE1-994
spellingShingle	Central serous chorioretinopathy CSCR CSC CSR NSAIDs bromfenac nepafenac subretinal fluid SRF. Ophthalmology RE1-994 Bahadorani S Maclean K Wannamaker K Chu ER Gresores N Sohn JH Diaz-Rohena R Singer MA Treatment of central serous chorioretinopathy with topical NSAIDs
description	Sepehr Bahadorani,1 Kyle Maclean,1 Kendall Wannamaker,1 Edward Rickie Chu,1 Nathan Gresores,2 Jeong-Hyeon Sohn,1 Roberto Diaz-Rohena,1 Michael A Singer21Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; 2Medical Center Ophthalmology Associates, San Antonio, TX, USAPurpose: Central serous chorioretinopathy (CSCR) is a common retinopathy that is often observed until resolution. The purpose of this study is to evaluate the effects of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on timing of CSCR recovery.Methods: An IRB-approved retrospective review was conducted on patients that had been diagnosed with a new-onset, symptomatic case of CSCR. Patients were either observed only (13 untreated eyes) or treated with topical bromfenac or nepafenac (14 eyes) over an average of about a 4–5 week follow-up period.Results: There was no statistical significance between central macular thickness (CMT) and visual acuity of treatment and control groups at the initial presentation. However, at the follow-up visit, CMT reductions in the treatment group were significantly higher than in the control group (p<0.006).Conclusion: Use of topical NSAIDs in the treatment of acute CSCR leads to a faster rate of reduction in the subretinal fluid volume over a follow-up period of a few weeks.Keywords: central serous chorioretinopathy, CSCR, CSC, NSAIDs, bromfenac, nepafenac, subretinal fluid, SRF
format	article
author	Bahadorani S Maclean K Wannamaker K Chu ER Gresores N Sohn JH Diaz-Rohena R Singer MA
author_facet	Bahadorani S Maclean K Wannamaker K Chu ER Gresores N Sohn JH Diaz-Rohena R Singer MA
author_sort	Bahadorani S
title	Treatment of central serous chorioretinopathy with topical NSAIDs
title_short	Treatment of central serous chorioretinopathy with topical NSAIDs
title_full	Treatment of central serous chorioretinopathy with topical NSAIDs
title_fullStr	Treatment of central serous chorioretinopathy with topical NSAIDs
title_full_unstemmed	Treatment of central serous chorioretinopathy with topical NSAIDs
title_sort	treatment of central serous chorioretinopathy with topical nsaids
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/3d09e27f5f2a41e68a9509b25d8f3f63
work_keys_str_mv	AT bahadoranis treatmentofcentralserouschorioretinopathywithtopicalnsaids AT macleank treatmentofcentralserouschorioretinopathywithtopicalnsaids AT wannamakerk treatmentofcentralserouschorioretinopathywithtopicalnsaids AT chuer treatmentofcentralserouschorioretinopathywithtopicalnsaids AT gresoresn treatmentofcentralserouschorioretinopathywithtopicalnsaids AT sohnjh treatmentofcentralserouschorioretinopathywithtopicalnsaids AT diazrohenar treatmentofcentralserouschorioretinopathywithtopicalnsaids AT singerma treatmentofcentralserouschorioretinopathywithtopicalnsaids
_version_	1718401177936199680

Treatment of central serous chorioretinopathy with topical NSAIDs

Ejemplares similares